Filing Flows › Dianthus Therapeutics (DNTH) › Q4 2025 › vs Q3 2025
Dianthus Therapeutics (DNTH) Q4 2025 vs Q3 2025 (quarter over quarter)
Dianthus Therapeutics's revenue fell $112K (-28%) from $396K in Q3 2025 to $284K in Q4 2025.
Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year), net loss $64.4M, operating cash flow −$47.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $284K | $396K | −$112K | -28% |
| Other income, net | $5.1M | $3.5M | $1.6M | +45% |
| Net loss | $64.4M | $36.8M | $27.7M | +75% |
| Costs & expenses | $69.8M | $40.7M | $29.1M | +72% |
| Operating costs | $69.8M | $40.7M | $29.1M | +72% |
| Research & development | $59.9M | $32.5M | $27.4M | +84% |
| General & admin | $9.9M | $8.2M | $1.7M | +21% |
| Operating cash sources | $64.4M | $36.8M | $27.7M | +75% |
| Depreciation | $27K | $27K | $0 | 0% |
| Share-based compensation | $6.0M | $5.8M | $184K | +3% |
| Working capital & other | $11.4M | $389K | $11.1M | 29× |
| Cash used in operations | $47.0M | $30.6M | $16.4M | +54% |
| Net loss absorbed | $64.4M | $36.8M | $27.7M | +75% |
Questions
How much did Dianthus Therapeutics's revenue grow quarter over quarter in Q4 2025?
Dianthus Therapeutics's revenue fell $112K (-28%) from $396K in Q3 2025 to $284K in Q4 2025.